04/23/2026
Rescheduling Is Underway… Now What?
As of this morning, 4/23/26, state-licensed medical cannabis products and FDA-approved cannabis medicine have been moved to Schedule III, with an expedited process underway for all cannabis. The rescheduling was officially signed by Acting Attorney General Todd Blanche yesterday, April 22. Here’s a clear breakdown of the expected short-term impact:
The most immediate effect: Tax Relief — The biggest near-term win for the cannabis industry is the removal of IRS code 280E, which has prevented cannabis businesses from deducting ordinary expenses — rent, payroll, utilities — from their federal taxes. Some cannabis businesses have been operating at effective tax rates of 70% or higher. The industry has paid an estimated $15 billion in excess taxes since 2018. That changes now for state-licensed medical ma*****na operators, freeing up significant cash flow for reinvestment and hiring.
Research opens up — Schedule III status removes the bureaucratic and legal barriers that have made rigorous cannabis research nearly impossible for decades. Expect an acceleration of clinical studies, particularly around medical applications.
Banking improves, but isn’t solved — Rescheduling doesn’t fully resolve the federal banking problem. Many banks still won’t touch cannabis businesses, but it reduces some of the risk perception and should strengthen banking relationships over time.
What it doesn’t do — Recreational cannabis in adult-use states remains federally illegal under Schedule I status pending a hearing process set for June 29. So the rescheduling currently applies most clearly to state-licensed medical ma*****na operators. It also doesn’t expunge any records or affect sentences for cannabis convictions.
The bottom line — this is a meaningful and long-overdue step, but it’s the beginning of a longer process, not the finish line.
We’ll keep watching and keep you informed.
🌿 Siskiyou Sungrown — grown in the sun, grounded in honesty.
